Response to highly active antiretroviral therapy according to duration of HIV infection

被引:0
|
作者
Pezzotti, P
Pappagallo, M
Phillips, PN
Boros, S
Valdarchi, C
Sinicco, A
Zaccarelli, M
Rezza, G
机构
[1] Ist Super Sanita, Reparto AIDS & MST, I-00161 Rome, Italy
[2] UCL Royal Free & Univ Coll Med Sch, London, England
[3] Univ Turin, Turin, Italy
[4] IRCCS L Spallanzani, Rome, Italy
关键词
antiretroviral therapy; HIV seroconverters; effectiveness; cohort study;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate whether duration of HIV-1 infection influences the response to highly active antiretroviral therapy (HAART). Design: Prospective study of individuals (Italian Seroconversion Study cohort) with well-estimated dates of HIV-1 seroconversion. Methods: This analysis included 277 participants who began HAART (defined as three antiretroviral drugs used in combination). Cox regression models were used to evaluate the association between duration of infection (as categorical variable [less than or equal to3, 3-7.5, >7.5 years from seroconversion] or continuous variable) and an immunologic (rise in CD4 count >100 cells/mm(3)) and a virologic (decline in plasma HIV-RNA to unquantifiable levels) outcome. All analyses were stratified by center of recruitment and adjustment, when used, was for gender, age at inception of HAART, injection drug use. previous antiretroviral therapy, lag-time between positive and negative HIV test result, year of starting HAART, clinical stage, CD4 count, and HIV-RNA at time of HAART. Results: HAART was initiated a median of 6.4 years after seroconversion, There was a median follow-up of 1.6 years after starting HAART to the calendar cut-off (November 1999). One-hundred-eighty-one (65.3%) patients experienced a decline in viral load to below quantifiable levels and 184 (66.4%) experienced a rise in CD4 >100 cells/mm(3). In the Cox models, by 1-year increase in duration of infection, we estimated a lower crude hazard of achieving a CD4 count increase >100 cells (relative hazard [RH], 0.96: 95% confidence interval [CI]. 0.92-1.01; p = .09), and a lower hazard of reaching an unquantifiable level of plasma HIV-RNA (RH, 0.97; 95%CI, 0.93-1.02; p = .20). After adjustment, these values became 0.99 (95%CI, 0.93-1.04; p = .62) and 0.98 (95%CI, 0.93-1.03; p = .48), respectively. When duration of HIV infection was considered as a categorical variable, the results were consistent with those already described. Conclusions: These results suggest that the duration of HIV infection does not seem to play an important independent role in determining the virologic and immunologic responses to HAART.
引用
收藏
页码:473 / 479
页数:7
相关论文
共 50 条
  • [1] Highly active Antiretroviral therapy and viral response in HIV type 2 infection
    Mullins, C
    Eisen, G
    Popper, S
    Sarr, AD
    Sankalé, JL
    Berger, JJ
    Wright, SB
    Chang, HR
    Coste, G
    Cooley, TP
    Rice, P
    Skolnik, PR
    Sullivan, M
    Kanki, PJ
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) : 1771 - 1779
  • [2] Epidermodysplasia verruciformis in a patient with HIV infection:: no response to highly active antiretroviral therapy
    Carré, D
    Dompmartin, A
    Verneuil, L
    Verdon, R
    Comoz, F
    Le Brun, E
    Freymuth, F
    Leroy, D
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (04) : 296 - 300
  • [3] Monitoring of highly active antiretroviral therapy in HIV infection
    Walker, A. Sarah
    Gibb, Diana M.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (01) : 27 - 33
  • [4] Highly active antiretroviral therapy for HIV infection: lessons for the future
    Burger, DM
    van der Ven, AJAM
    Koopmans, PP
    NETHERLANDS JOURNAL OF MEDICINE, 2004, 62 (11): : 407 - 408
  • [5] HIV infection, highly active antiretroviral therapy and the cardiovascular system
    Barbaro, G
    CARDIOVASCULAR RESEARCH, 2003, 60 (01) : 87 - 95
  • [6] Sarcoidosis and HIV infection: Influence of highly active antiretroviral therapy
    Blanche, P
    Passeron, A
    Gombert, B
    Ginsburg, C
    Salmon, D
    Sicard, D
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (06) : 1185 - 1185
  • [7] The neuropathology of HIV infection in the era of highly active antiretroviral therapy
    Vallat-Decouvelaere, AV
    Chrétien, F
    de la Grandmaison, GL
    Carlier, R
    Force, G
    Gray, F
    ANNALES DE PATHOLOGIE, 2003, 23 (05) : 408 - 423
  • [8] Ten years of highly active antiretroviral therapy for HIV infection
    Chen, Luke F.
    Hoy, Jennifer
    Lewin, Sharon R.
    MEDICAL JOURNAL OF AUSTRALIA, 2007, 186 (03) : 146 - 151
  • [9] Duration of highly active antiretroviral therapy regimens
    Chen, RY
    Westfall, AO
    Mugavero, MJ
    Cloud, GA
    Raper, JL
    Chatham, AG
    Acosta, EP
    Taylor, KH
    Carter, J
    Saag, MS
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) : 714 - 722
  • [10] Duration of highly active antiretroviral therapy regimens
    Sanchez, F. Marcos
    Castano, M. I. Albo
    Blanco, S. Casallo
    Loarte, P. del Valle
    Domingo, A. Herrero
    ANALES DE MEDICINA INTERNA, 2007, 24 (05) : 256 - 257